Compare Dishman Pharma with Lupin - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DISHMAN PHARMA vs LUPIN - Comparison Results

DISHMAN PHARMA     Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

LUPIN 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DISHMAN PHARMA LUPIN DISHMAN PHARMA/
LUPIN
 
P/E (TTM) x 25.1 42.4 59.2% View Chart
P/BV x 3.3 3.9 85.9% View Chart
Dividend Yield % 0.7 0.6 119.5%  

Financials

 DISHMAN PHARMA   LUPIN
EQUITY SHARE DATA
    DISHMAN PHARMA
Mar-16
LUPIN
Mar-20
DISHMAN PHARMA/
LUPIN
5-Yr Chart
Click to enlarge
High Rs374882 42.4%   
Low Rs129505 25.5%   
Sales per share (Unadj.) Rs197.8339.4 58.3%  
Earnings per share (Unadj.) Rs21.2-5.9 -356.6%  
Cash flow per share (Unadj.) Rs34.715.5 224.4%  
Dividends per share (Unadj.) Rs2.006.00 33.3%  
Dividend yield (eoy) %0.80.9 91.9%  
Book value per share (Unadj.) Rs179.9276.7 65.0%  
Shares outstanding (eoy) m80.69453.00 17.8%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x1.32.0 62.3%   
Avg P/E ratio x11.9-116.6 -10.2%  
P/CF ratio (eoy) x7.244.8 16.2%  
Price / Book Value ratio x1.42.5 55.8%  
Dividend payout %9.4-100.9 -9.3%   
Avg Mkt Cap Rs m20,306314,201 6.5%   
No. of employees `0000.818.3 4.5%   
Total wages/salary Rs m5,35529,868 17.9%   
Avg. sales/employee Rs Th19,252.78,400.6 229.2%   
Avg. wages/employee Rs Th6,459.51,632.0 395.8%   
Avg. net profit/employee Rs Th2,064.1-147.2 -1,402.3%   
INCOME DATA
Net Sales Rs m15,961153,748 10.4%  
Other income Rs m2654,838 5.5%   
Total revenues Rs m16,226158,585 10.2%   
Gross profit Rs m4,10324,849 16.5%  
Depreciation Rs m1,0919,702 11.2%   
Interest Rs m9443,630 26.0%   
Profit before tax Rs m2,33416,355 14.3%   
Minority Interest Rs m04 0.0%   
Prior Period Items Rs m139 2.8%   
Extraordinary Inc (Exp) Rs m0-7,521 0.0%   
Tax Rs m62411,571 5.4%   
Profit after tax Rs m1,711-2,694 -63.5%  
Gross profit margin %25.716.2 159.1%  
Effective tax rate %26.770.8 37.8%   
Net profit margin %10.7-1.8 -611.9%  
BALANCE SHEET DATA
Current assets Rs m11,018154,132 7.1%   
Current liabilities Rs m9,51792,252 10.3%   
Net working cap to sales %9.440.2 23.4%  
Current ratio x1.21.7 69.3%  
Inventory Days Days11082 134.6%  
Debtors Days Days35129 26.9%  
Net fixed assets Rs m16,30489,082 18.3%   
Share capital Rs m161906 17.8%   
"Free" reserves Rs m12,907124,461 10.4%   
Net worth Rs m14,516125,367 11.6%   
Long term debt Rs m4,18917,933 23.4%   
Total assets Rs m29,805249,839 11.9%  
Interest coverage x3.55.5 63.0%   
Debt to equity ratio x0.30.1 201.8%  
Sales to assets ratio x0.50.6 87.0%   
Return on assets %8.90.4 2,378.4%  
Return on equity %11.8-2.1 -548.6%  
Return on capital %17.58.7 200.9%  
Exports to sales %24.80-   
Imports to sales %3.70-   
Exports (fob) Rs m3,956NA-   
Imports (cif) Rs m596NA-   
Fx inflow Rs m4,95251,450 9.6%   
Fx outflow Rs m69719,470 3.6%   
Net fx Rs m4,25531,980 13.3%   
CASH FLOW
From Operations Rs m2,78614,688 19.0%  
From Investments Rs m-1,52911,070 -13.8%  
From Financial Activity Rs m-941-8,906 10.6%  
Net Cashflow Rs m31616,853 1.9%  

Share Holding

Indian Promoters % 61.4 46.6 131.8%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 3.7 11.3 32.7%  
FIIs % 12.7 31.9 39.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.1 10.1 218.8%  
Shareholders   46,261 98,259 47.1%  
Pledged promoter(s) holding % 35.8 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DISHMAN PHARMA With:   CIPLA  PIRAMAL ENTERPRISES  ALKEM LABORATORIES  SHASUN PHARMA  PFIZER  

Compare DISHMAN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 154 Points Lower, Nifty Ends at 14,834; Bajaj Finance and UPL Among Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended marginally lower.

Related Views on News

LUPIN 2019-20 Annual Report Analysis (Annual Result Update)

Dec 7, 2020 | Updated on Dec 7, 2020

Here's an analysis of the annual report of LUPIN for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of LUPIN. Also includes updates on the valuation of LUPIN.

LUPIN Announces Quarterly Results (2QFY21); Net Profit Up 271.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, LUPIN has posted a net profit of Rs 2 bn (up 271.3% YoY). Sales on the other hand came in at Rs 38 bn (down 12.0% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (1QFY21); Net Profit Down 64.2% (Quarterly Result Update)

Aug 18, 2020 | Updated on Aug 18, 2020

For the quarter ended June 2020, LUPIN has posted a net profit of Rs 1 bn (down 64.2% YoY). Sales on the other hand came in at Rs 35 bn (down 20.2% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (4QFY20); Net Profit Up 35.5% (Quarterly Result Update)

Jun 1, 2020 | Updated on Jun 1, 2020

For the quarter ended March 2020, LUPIN has posted a net profit of Rs 4 bn (up 35.5% YoY). Sales on the other hand came in at Rs 38 bn (down 12.7% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN Announces Quarterly Results (2QFY20); Net Profit Down 146.4% (Quarterly Result Update)

Nov 7, 2019 | Updated on Nov 7, 2019

For the quarter ended September 2019, LUPIN has posted a net profit of Rs 1 bn (down 146.4% YoY). Sales on the other hand came in at Rs 44 bn (up 10.3% YoY). Read on for a complete analysis of LUPIN's quarterly results.

More Views on News

Most Popular

A Critical Update on the Market(Fast Profits Daily)

Mar 30, 2021

In this video, I'll tell you why I am recommending caution in the market at this time.

My Recent Recommendation Will Profit from the Global Supply Chain Crisis(Profit Hunter)

Mar 31, 2021

A tiny chemical company, started in the Licence Raj era, is a great example of a new wealth creating opportunity.

My Stock Trading Strategy(Fast Profits Daily)

Mar 31, 2021

In this video I'll show you exactly how I go about picking stocks for trading.

What You Need to Find Hundred Baggers(Profit Hunter)

Mar 30, 2021

100 baggers of the last decade share this common trait. Here's how to use it to nail future multibaggers.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

DISHMAN PHARMA SHARE PRICE


May 29, 2017 (Close)

TRACK DISHMAN PHARMA

  • Track your investment in DISHMAN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DISHMAN PHARMA

DISHMAN PHARMA 8-QTR ANALYSIS

COMPARE DISHMAN PHARMA WITH

MARKET STATS